Table 4 Prevalence of (level I/II evidence for) risk factors for the development of febrile neutropenia (according to ASCO and EORTC guidelines)

From: A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

Risk factor (level I/II evidence)

Number of cases, n =71 (%)

Advanced disease

39 (54)

Age ⩾65 years

25 (35)

Previous neutropenic event

18 (25)

No prophylactic treatment (G-CSF and/or antibiotic treatment)

43 (60)

Chemotherapy ≥20% risk for febrile neutropenia

23 (32)

  1. Abbreviations: ASCO=American Society of Clinical Oncology; EORTC=European Organisation of Research and Treatment of Cancer; G-CSF=granulocyte colony-stimulating factor.
Back to article page